These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31805182)

  • 1. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
    Brandão LR; Albisetti M; Halton J; Bomgaars L; Chalmers E; Mitchell LG; Nurmeev I; Svirin P; Kuhn T; Zapletal O; Tartakovsky I; Simetzberger M; Huang F; Sun Z; Kreuzer J; Gropper S; Brueckmann M; Luciani M;
    Blood; 2020 Feb; 135(7):491-504. PubMed ID: 31805182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
    Halton J; Brandão LR; Luciani M; Bomgaars L; Chalmers E; Mitchell LG; Nurmeev I; Sharathkumar A; Svirin P; Gorbatikov K; Tartakovsky I; Simetzberger M; Huang F; Sun Z; Kreuzer J; Gropper S; Reilly P; Brueckmann M; Albisetti M;
    Lancet Haematol; 2021 Jan; 8(1):e22-e33. PubMed ID: 33290737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability.
    Halton JML; Albisetti M; Biss B; Bomgaars L; Brueckmann M; Gropper S; Harper R; Huang F; Luciani M; Maas H; Tartakovsky I; Mitchell LG
    J Thromb Haemost; 2017 Nov; 15(11):2147-2157. PubMed ID: 28921890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia.
    Brandão LR; Tartakovsky I; Albisetti M; Halton J; Bomgaars L; Chalmers E; Luciani M; Saracco P; Felgenhauer J; Lvova O; Simetzberger M; Sun Z; Mitchell LG
    Blood Adv; 2022 Nov; 6(22):5908-5923. PubMed ID: 36150047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabigatran Etexilate: A Review in Pediatric Venous Thromboembolism.
    Paik J
    Paediatr Drugs; 2022 Jul; 24(4):423-431. PubMed ID: 35699915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK.
    Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T
    Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence.
    Greig SL; McKeage K
    Drugs; 2014 Oct; 74(15):1785-800. PubMed ID: 25270377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism.
    Halton JML; Picard AC; Harper R; Huang F; Brueckmann M; Gropper S; Maas H; Tartakovsky I; Nurmeev I; Mitchell LG; Brandão LR; Chalmers E; Albisetti M
    Thromb Haemost; 2017 Nov; 117(11):2168-2175. PubMed ID: 29202215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER™ II, and RE-MEDY™.
    Goldhaber SZ; Eriksson H; Kakkar A; Schellong S; Feuring M; Fraessdorf M; Kreuzer J; Schueler E; Schulman S
    Vasc Med; 2016 Dec; 21(6):506-514. PubMed ID: 27807306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
    Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S
    PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL
    Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational study of dabigatran etexilate 150mg in patients with moderate renal impairment undergoing elective total hip or knee replacement.
    Samama CM; Rosencher N; Kleine E; Feuring M; Brueckmann M; Clemens A; Gullberg J; Frostick SP
    Thromb Res; 2016 Jul; 143():103-10. PubMed ID: 27208980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability and clinical pharmacology of dabigatran etexilate in adolescents. An open-label phase IIa study.
    Halton JM; Lehr T; Cronin L; Lobmeyer MT; Haertter S; Belletrutti M; Mitchell LG
    Thromb Haemost; 2016 Aug; 116(3):461-71. PubMed ID: 27357738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design.
    Luciani M; Albisetti M; Biss B; Bomgaars L; Brueckmann M; Chalmers E; Gropper S; Halton JML; Harper R; Huang F; Manastirski I; Mitchell LG; Tartakovsky I; Wang B; Brandão LR
    Res Pract Thromb Haemost; 2018 Jul; 2(3):580-590. PubMed ID: 30046763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and rationale for the DIVERSITY study: An open-label, randomized study of dabigatran etexilate for pediatric venous thromboembolism.
    Albisetti M; Biss B; Bomgaars L; Brandão LR; Brueckmann M; Chalmers E; Gropper S; Harper R; Huang F; Luciani M; Manastirski I; Mitchell LG; Tartakovsky I; Wang B; Halton JML
    Res Pract Thromb Haemost; 2018 Apr; 2(2):347-356. PubMed ID: 30046738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran for the treatment of venous thromboembolism.
    Schellong SM
    Expert Rev Hematol; 2015 Aug; 8(4):413-25. PubMed ID: 26111881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
    Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
    Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.